139 related articles for article (PubMed ID: 29360962)
1. Low Doses of Azathioprine are Effective in Combination With Infliximab in Inflammatory Bowel Disease but May not be During Induction Therapy.
Roblin X; Flourié B; Paul S
J Crohns Colitis; 2018 Apr; 12(5):628. PubMed ID: 29360962
[No Abstract] [Full Text] [Related]
2. Inflammatory bowel disease in the clinic: Escalation and de-escalation of therapy: A longitudinal case-based discussion.
Begun J
J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():12-3. PubMed ID: 26990807
[No Abstract] [Full Text] [Related]
3. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.
Drobne D; Kurent T; Golob S; Švegl P; Rajar P; Hanžel J; Koželj M; Novak G; Smrekar N; Ferkolj I; Štabuc B
Aliment Pharmacol Ther; 2019 Apr; 49(7):880-889. PubMed ID: 30784100
[TBL] [Abstract][Full Text] [Related]
4. Thiopurine-S-methyltransferase genotype and the response to azathioprine in inflammatory bowel disease.
Stocco G; Martelossi S; Decorti G; Bartoli F; Ventura A
Aliment Pharmacol Ther; 2007 Oct; 26(7):1083-4; author reply 1084-5. PubMed ID: 17877516
[No Abstract] [Full Text] [Related]
5. Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.
Kiszka-Kanowitz M; Theede K; Mertz-Nielsen A
Scand J Gastroenterol; 2016 Dec; 51(12):1470-1475. PubMed ID: 27686002
[TBL] [Abstract][Full Text] [Related]
6. Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center.
Orlando A; Renna S; Rizzuto G; Orlando E; Affronti M; Cottone M
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):914. PubMed ID: 26707682
[No Abstract] [Full Text] [Related]
7. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
Roblin X; Boschetti G; Williet N; Nancey S; Marotte H; Berger A; Phelip JM; Peyrin-Biroulet L; Colombel JF; Del Tedesco E; Paul S; Flourie B
Aliment Pharmacol Ther; 2017 Jul; 46(2):142-149. PubMed ID: 28449228
[TBL] [Abstract][Full Text] [Related]
8. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2015 Jun; 177(26):1253-5. PubMed ID: 26550625
[TBL] [Abstract][Full Text] [Related]
9. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
[TBL] [Abstract][Full Text] [Related]
10. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
[TBL] [Abstract][Full Text] [Related]
11. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.
Andrade P; Santos-Antunes J; Rodrigues S; Lopes S; Macedo G
J Gastroenterol Hepatol; 2015 Nov; 30(11):1591-5. PubMed ID: 25967740
[TBL] [Abstract][Full Text] [Related]
12. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
13. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
Shah JA; Edwards CM; Probert CS
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):169-73. PubMed ID: 18301295
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.
Tighe D; McNamara D
World J Gastroenterol; 2017 Jan; 23(3):414-425. PubMed ID: 28210077
[TBL] [Abstract][Full Text] [Related]
15. The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model.
Scott FI; Vajravelu RK; Bewtra M; Mamtani R; Lee D; Goldberg DS; Lewis JD
Clin Gastroenterol Hepatol; 2015 Feb; 13(2):302-309.e11. PubMed ID: 25117775
[TBL] [Abstract][Full Text] [Related]
16. Azathioprine: when less is more.
Duley JA; Florin TH
J Gastroenterol Hepatol; 2008 Sep; 23(9):1317-9. PubMed ID: 18853992
[No Abstract] [Full Text] [Related]
17. Thiopurines best practice.
Friedman A
J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():6-7. PubMed ID: 26990458
[No Abstract] [Full Text] [Related]
18. Azathioprine Therapy in a Pediatric TPMT-Deficient Patient-Still an Option.
van Moorsel SA; Bevers N; Meurs M; van Rossum LK; Hooymans PM; Wong DR
Ther Drug Monit; 2017 Feb; 39(1):1-4. PubMed ID: 28081040
[TBL] [Abstract][Full Text] [Related]
19. Azathioprine in inflammatory bowel disease, a safe alternative?
Tanis AA
Mediators Inflamm; 1998; 7(3):141-4. PubMed ID: 9705598
[TBL] [Abstract][Full Text] [Related]
20. Awareness of adverse effects of azathioprine in patients with inflammatory bowel disease--more to be done?
Spence AD; Lee R; Keegan D; Doherty GA; Mulcahy H; Murphy S
Ulster Med J; 2014 Jan; 83(1):56-7. PubMed ID: 24757277
[No Abstract] [Full Text] [Related]
[Next] [New Search]
